HOME >> BIOLOGY >> NEWS
Columbia researcher identifies cellular defect that may contribute to autism

NEW YORK, NY, January 27 The causes of autism have long remained a mystery, but new research from Columbia University Medical Center has identified, for the first time, how a cellular defect may be involved in the often crippling neurological disorder.

The research, which is published in today's issue of Science, examines how a defect in neuroligin genes may contribute to autism. Neuroligins are components of synapses, which connect individual neurons in the brain. The researchers found that the loss of neuroligins perturbs the formation of neuronal connections and results in an imbalance of neuronal function. This imbalance provides an explanation for the neurodevelopmental defects in autistic children.

"Understanding the cellular defects that may underlie autism-spectrum disorders represents an important step towards the goal of providing therapies," said Peter Scheiffele, Ph.D., assistant professor of physiology and cellular biophysics at Columbia University Medical Center, and principal investigator on the study.

A defect in the neuroligin genes had previously been observed in autistic patients, but its functional significance was not yet understood. Scheiffele's study showed that in rat neurons without any neuroligin, connections between neurons are altered in a way that is strikingly similar to those found in autistic children.

Each neuron in the brain receives many different inputs some are excitatory and signal the neuron to fire, and some are inhibitory and signal the neuron to stop firing. Scheiffele's research team found that neuroligin genes are responsible for regulating the balance between excitatory and inhibitory synaptic function. A defect in neuroligin leads to a selective loss in inhibitory function and thereby impairs the fine-tuning of neuronal connectivity, a neurological problem that is understood to play a role in autism.

"There is much we still don't know about how neurons con
'"/>

Contact: Craig LeMoult
cel2113@columbia.edu
212-305-0820
Columbia University Medical Center
27-Jan-2005


Page: 1 2

Related biology news :

1. Columbia University Medical Center awarded $3 million to drive Alzheimers genetics research
2. Columbia scientists determine 3-dimensional structure of cells fuel gauge
3. Columbia University licenses next-generation DNA sequencing technology
4. New bird discovered on unexplored Columbian mountain
5. Columbia University Medical Center receives major new NIH Clinical Science investment funds
6. Columbia University awards 2006 Horwitz Prize to biologist who explained gene transcription
7. Columbia University receives $16.9 million NIEHS award to study arsenic in ground water
8. Contaminants linked to sturgeon decline in Columbia river
9. Columbia University Medical Center researchers discover potential mechanism for tumor growth
10. UF, Columbia scientists closer to new cancer detection method
11. Columbia University awards 2005 Horwitz Prize to Israeli structural biologist

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology:
Cached News: